S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
S&P 500   3,913.95 (-0.25%)
DOW   31,319.54 (-0.54%)
QQQ   291.21 (+0.02%)
AAPL   137.56 (-2.32%)
MSFT   253.71 (-0.15%)
FB   192.72 (+0.25%)
GOOGL   2,212.80 (-1.13%)
AMZN   2,165.00 (+1.06%)
TSLA   715.18 (+0.76%)
NVDA   173.97 (+2.71%)
BABA   88.23 (+1.05%)
NIO   16.76 (+5.87%)
AMD   98.53 (+2.34%)
CGC   5.96 (+6.62%)
MU   70.29 (-1.07%)
T   20.17 (-0.30%)
GE   75.79 (+0.78%)
F   13.00 (+1.72%)
DIS   103.73 (-0.55%)
AMC   12.95 (+1.49%)
PFE   50.44 (+0.08%)
PYPL   81.64 (+5.78%)
NFLX   185.44 (+4.66%)
LON:HIK

Hikma Pharmaceuticals (HIK) Share Forecast, Price & News

GBX 1,703.48
+24.98 (+1.49%)
(As of 05/19/2022 05:20 PM ET)
Add
Compare
Today's Range
1,671.50
1,708.50
50-Day Range
1,678.50
2,129
52-Week Range
1,651.50
2,703
Volume
1.07 million shs
Average Volume
686,963 shs
Market Capitalization
£3.85 billion
P/E Ratio
11.56
Dividend Yield
2.26%
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals logo

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
8,700
Year Founded
N/A

Sales & Book Value

Annual Sales
£2.55 billion
Cash Flow
GBX 194.68 per share
Book Value
GBX 1,059.60 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£3.85 billion
Optionable
Not Optionable

Company Calendar

Ex-Dividend for 4/28 Dividend
3/17/2022
Dividend Payable
4/28/2022
Today
5/19/2022
Next Earnings (Estimated)
8/04/2022

MarketRank

Overall MarketRank

2.28 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals
or view top-rated stocks.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Hikma Pharmaceuticals
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, February 24th. Stockholders of record on Thursday, March 17th will be paid a dividend of GBX 0.36 per share on Thursday, April 28th. This represents a yield of 1.32%. The ex-dividend date is Thursday, March 17th. This is a boost from Hikma Pharmaceuticals's previous dividend of GBX 0.18. The official announcement can be viewed at this link.
View Hikma Pharmaceuticals' dividend history
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 2.26%. The dividend payout ratio of Hikma Pharmaceuticals is 0.35%. This payout ratio is at a healthy, sustainable level, below 75%.
View Hikma Pharmaceuticals' dividend history.

What price target have analysts set for HIK?

6 analysts have issued 1 year target prices for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 2,300 to GBX 2,880. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 2,580 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for Hikma Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Hikma Pharmaceuticals' key executives?
Hikma Pharmaceuticals' management team includes the following people:
  • Engineer Said Samih Taleb Darwazah, Exec. Chairman (Age 65, Pay $2.71M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 53, Pay $3.26M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 64, Pay $2.11M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 50)
  • Ms. Henriette Nielsen, Exec. VP of Bus. Operations
  • Dr. Shahin Fesharaki, Chief Scientific Officer
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA, CPA, Exec. VP of Corp. Devel. and M&A (Age 57)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.
What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,703.48.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of £3.85 billion and generates £2.55 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,700 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.